151 related articles for article (PubMed ID: 33303501)
1. Rare case of clear cell renal cell carcinoma presenting as a unilateral tonsil lesion.
Ellis SD; Meikle A; Al-Salti W; Sinclair G
BMJ Case Rep; 2020 Dec; 13(12):. PubMed ID: 33303501
[TBL] [Abstract][Full Text] [Related]
2. Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports.
Négrier S; Moriceau G; Attignon V; Haddad V; Pissaloux D; Guerin N; Carrie C
J Med Case Rep; 2018 Nov; 12(1):351. PubMed ID: 30474572
[TBL] [Abstract][Full Text] [Related]
3. Exceptional Response to Cabozantinib of Rapidly Evolving Brain Metastases of Renal Cell Carcinoma: A Case Report and Review of the Literature.
Ciccarese C; Iacovelli R; Mosillo C; Tortora G
Clin Genitourin Cancer; 2018 Oct; 16(5):e1069-e1071. PubMed ID: 30005936
[No Abstract] [Full Text] [Related]
4. Cabozantinib inhibits tumor growth and metastasis of a patient-derived xenograft model of papillary renal cell carcinoma with MET mutation.
Zhao H; Nolley R; Chan AMW; Rankin EB; Peehl DM
Cancer Biol Ther; 2017 Nov; 18(11):863-871. PubMed ID: 27715452
[TBL] [Abstract][Full Text] [Related]
5. Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial.
Escudier B; Powles T; Motzer RJ; Olencki T; Arén Frontera O; Oudard S; Rolland F; Tomczak P; Castellano D; Appleman LJ; Drabkin H; Vaena D; Milwee S; Youkstetter J; Lougheed JC; Bracarda S; Choueiri TK
J Clin Oncol; 2018 Mar; 36(8):765-772. PubMed ID: 29309249
[TBL] [Abstract][Full Text] [Related]
6. Cabozantinib for Treatment of Brain Metastases in Patients With Renal Cell Carcinoma.
Rizzo A; Mollica V; Massari F
JAMA Oncol; 2022 May; 8(5):783-784. PubMed ID: 35238907
[No Abstract] [Full Text] [Related]
7. Cabozantinib for Treatment of Brain Metastases in Patients With Renal Cell Carcinoma.
Zhao B; Ma W
JAMA Oncol; 2022 May; 8(5):783. PubMed ID: 35238875
[No Abstract] [Full Text] [Related]
8. Progression of Cabozantinib-Related Osteonecrosis Mimicking Metastases on Bone Scan.
Xu G; Lu Y
Clin Nucl Med; 2021 Jul; 46(7):592-594. PubMed ID: 33577198
[TBL] [Abstract][Full Text] [Related]
9. [Cabozantinib: Mechanism of action, efficacy and indications].
Cochin V; Gross-Goupil M; Ravaud A; Godbert Y; Le Moulec S
Bull Cancer; 2017 May; 104(5):393-401. PubMed ID: 28477875
[TBL] [Abstract][Full Text] [Related]
10. [Brain metastasis which appeared during complete response of lung metastatic lesion by sunitinib treatment in a patient with renal cell carcinoma].
Morizawa Y; Momose H; Toyoshima Y; Takada S; Fujimoto K; Oyama N
Hinyokika Kiyo; 2013 Dec; 59(12):791-3. PubMed ID: 24419011
[TBL] [Abstract][Full Text] [Related]
11. In brief: Cabozantinib (Cabometyx) for advanced renal cell carcinoma.
Med Lett Drugs Ther; 2016 Jul; 58(1499):e97. PubMed ID: 27403787
[No Abstract] [Full Text] [Related]
12. Hand-foot skin reaction with primarily dorsal involvement in a patient with metastatic renal cell carcinoma on cabozantinib.
Goyal A; Jacobsen AA; O'Leary D; Watson A; Luikart S; Gaddis KJ
Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941722
[TBL] [Abstract][Full Text] [Related]
13. Cabozantinib in the treatment of metastatic renal cell carcinoma - final data analysis from four oncology centers in the Czech Republic.
Richter I; Poprach A; Zemánková A; Büchler T; Bartoš J; Šámal V; Študentová H; Rozsypalová A; Dvořák J; Brom O; Melichar B
Klin Onkol; 2021; 34(5):392-400. PubMed ID: 34915708
[TBL] [Abstract][Full Text] [Related]
14. Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer.
Di Nunno V; Cimadamore A; Santoni M; Scarpelli M; Fiorentino M; Ciccarese C; Iacovelli R; Cheng L; Lopez-Beltran A; Massari F; Montironi R
Future Oncol; 2018 Oct; 14(25):2559-2564. PubMed ID: 30141348
[No Abstract] [Full Text] [Related]
15. CaboPoint: a phase II study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinoma.
Albiges L; Schmidinger M; Taguieva-Pioger N; Perol D; Grünwald V; Guemas E
Future Oncol; 2022 Mar; 18(8):915-926. PubMed ID: 34911359
[TBL] [Abstract][Full Text] [Related]
16. [New EMA approval: Nivolumab plus Cabozantinib for advanced renal clear cell carcinoma].
Naoun N; Vano YA
Bull Cancer; 2021 Nov; 108(11):991-993. PubMed ID: 34538614
[No Abstract] [Full Text] [Related]
17. Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program.
Albiges L; Fléchon A; Chevreau C; Topart D; Gravis G; Oudard S; Tourani JM; Geoffrois L; Meriaux E; Thiery-Vuillemin A; Barthélémy P; Ladoire S; Laguerre B; Perrot V; Billard A; Escudier B; Gross-Goupil M
Eur J Cancer; 2021 Jan; 142():102-111. PubMed ID: 33253997
[TBL] [Abstract][Full Text] [Related]
18. Influence of Prior Tyrosine Kinase Inhibitor on Survival for Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab or Cabozantinib: Data from a Literature-based Meta-analysis.
Roviello G; Generali D
Eur Urol; 2017 Dec; 72(6):1027-1028. PubMed ID: 28760645
[No Abstract] [Full Text] [Related]
19. An overview of the clinical use of cabozantinib in the treatment of advanced non-clear-cell renal cell carcinoma (NCCRCC).
D'Angelo A; Bagby S; Di Pierro G; Chirra M; Nobili S; Mini E; Villari D; Roviello G
Crit Rev Oncol Hematol; 2020 May; 149():102921. PubMed ID: 32172222
[TBL] [Abstract][Full Text] [Related]
20. Asymptomatic stroke is an underestimated side effect of cabozantinib.
Bronnimann C; Sibon I; Ravaud A; Gross-Goupil M
Rev Neurol (Paris); 2019 Jun; 175(6):409-410. PubMed ID: 31056194
[No Abstract] [Full Text] [Related]
[Next] [New Search]
